Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318762 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1MGAMSI | |
| SCHEMBL287865 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1MGAMSI | |
| SCHEMBL8970781 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1MGAMSI | |
| SCHEMBL557541 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1MGAMSI | |
| SCHEMBL19859337 | 0.88 | MPI (0.34) | LMNAL3MBTL1MGAMSIMPI | |
| SCHEMBL19859338 | 0.88 | MPI (0.34) | LMNAL3MBTL1MGAMSIMPI | |
| SCHEMBL3142523 | 0.88 | AKR1B1 (0.37) | LMNAL3MBTL1AKR1B1MPI | |
| SCHEMBL5453628 | 0.88 | AKR1B1 (0.37) | LMNAL3MBTL1AKR1B1MPI | |
| SCHEMBL183626 | 0.88 | AKR1B1 (0.37) | LMNAL3MBTL1AKR1B1MPI | |
| SCHEMBL5770928 | 0.88 | AKR1B1 (0.37) | LMNAL3MBTL1AKR1B1MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287214-A1 | CHLORELLA MANNOGALACTAN OR SULFATED CHLORELLA MANNOGALACTAN COMPOUND AND APPLICATION OF SULFATED CHLORELLA MANNOGALACTAN COMPOUND | GUANGXI UNIVERSITY OF CHINESE MEDICINE (CN) | 2024-08-29 | — | — | US | claimed |
| CN-116535532-B | Chlorella mannogalactan or sulfate compound and application thereof | 广西中医药大学 | 2024-03-29 | — | — | CN | claimed |
| CN-116535532-A | Chlorella mannogalactan or sulfate compound and application thereof | 广西中医药大学 | 2023-08-04 | — | — | CN | claimed |
| EP-2150620-B1 | Method for preparing C-6 phosphorylated D-aldohexoses and C-6 phosphorylated D-aldohexose derivatives, and new C-6 phosphorylated D-aldohexose derivatives | LIBRAGEN (FR) | 2011-08-10 | — | — | EP | claimed |
| EP-2150620-A2 | METHOD FOR PREPARING C-6 PHOSPHORYLATED D-ALDOHEXOSES AND C-6 PHOSPHORYLATED D-ALDOHEXOSE DERIVATIVES, AND NEW C-6 PHOSPHORYLATED D-ALDOHEXOSE DERIVATIVES | Libragen (FR) | 2010-02-10 | — | — | EP | claimed |
| WO-2008142155-A2 | METHOD FOR PREPARING C-6 PHOSPHORYLATED D-ALDOHEXOSES AND C-6 PHOSPHORYLATED D-ALDOHEXOSES DERIVATIVES AND NEW C-6 PHOSPHORYLATED D-ALDOHEXOSES DERIVATIVES | LIBRAGEN (FR) | 2008-11-27 | — | — | WO | claimed |
| EP-1995323-A1 | Method for preparing C-6 phosphorylated D-aldohexoses and C-6 phosphorylated D-aldohexose derivatives | Libragen (FR) | 2008-11-26 | — | — | EP | claimed |
| EP-4619030-A2 | MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF | Janssen Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250222093-A1 | METHODS OF PRODUCING BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | Janssen Pharmaceuticals, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-20250222088-A1 | MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF | Janssen Pharmaceuticals, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-20250161428-A1 | PREVENTING/TREATING PSEUDOMONAS AERUGINOSA INFECTION | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2025-05-22 | — | — | US | disclosed |
| US-12290563-B2 | Production of E. coli 018 bioconjugates | Janssen Pharmaceuticals, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-113950524-B | Methods of producing bioconjugates of E.coli O-antigen polysaccharides, compositions thereof, and methods of use thereof | 杨森制药公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-0596937-B1 | PLASMALOPSYCHOSINES AND PLASMALOCEREBROSIDES AND METHODS OF TREATING NEURONAL DISEASES EMPLOYING THE SAME | ONCOMEMBRANE INC (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| US-5693620-A | Plasmalopsychosines and plasmalocerebrosides | ONCOMEMBRANE, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0596937-A4 | PLASMALOPSYCHOSINES AND PLASMALOCEREBROSIDES AND METHODS OF TREATING NEURONAL DISEASES EMPLOYING THE SAME. | BIOMEMBRANE INST (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0596937-A1 | PLASMALOPSYCHOSINES AND PLASMALOCEREBROSIDES AND METHODS OF TREATING NEURONAL DISEASES EMPLOYING THE SAME | ONCOMEMBRANE, INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993002685-A1 | PLASMALOPSYCHOSINES AND PLASMALOCEREBROSIDES AND METHODS OF TREATING NEURONAL DISEASES EMPLOYING THE SAME | THE BIOMEMBRANE INSTITUTE (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222093-A1 | METHODS OF PRODUCING BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | OSTC, PGLS, ENGASE | LMNA 2811/4885L3MBTL1 489/4885TDP1 2650/4885 |
| US-20250222088-A1 | MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF | MLEC, ENGASE, CD63 | LMNA 2883/4885L3MBTL1 2054/4885TDP1 4537/4885 |
| US-12290563-B2 | Production of E. coli 018 bioconjugates | O60361, OGA, ENY2 | LMNA 4368/4885L3MBTL1 1342/4885TDP1 2903/4885 |
| US-20250161428-A1 | PREVENTING/TREATING PSEUDOMONAS AERUGINOSA INFECTION | SIGLEC7, CD47, SELP | LMNA 4850/4885L3MBTL1 2022/4885TDP1 4764/4885 |
| US-20240287214-A1 | CHLORELLA MANNOGALACTAN OR SULFATED CHLORELLA MANNOGALACTAN COMPOUND AND APPLICATION OF SULFATED CHLORELLA MANNOGALACTAN COMPOUND | MAN2A1, ALG1, ST3GAL3 | LMNA 948/4885L3MBTL1 2849/4885TDP1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.